Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Multi-center, Three Arm (Pritelivir, Placebo and Zovirax) Parallel Group, Comparative Trial to Assess the Efficacy and Safety of Pritelivir 5% w/w Ointment for the Treatment of Recurrent Herpes Labialis in Adults - LipP1

X
Trial Profile

A Randomized, Double-blind, Multi-center, Three Arm (Pritelivir, Placebo and Zovirax) Parallel Group, Comparative Trial to Assess the Efficacy and Safety of Pritelivir 5% w/w Ointment for the Treatment of Recurrent Herpes Labialis in Adults - LipP1

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pritelivir (Primary) ; Aciclovir
  • Indications Herpes labialis
  • Focus Therapeutic Use
  • Acronyms LipP1
  • Sponsors AiCuris
  • Most Recent Events

    • 13 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 06 Sep 2017 Planned End Date changed from 1 Aug 2017 to 1 Sep 2017.
    • 10 Aug 2017 Planned End Date changed from 1 Jul 2017 to 1 Aug 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top